An AFP-derived peptide-loaded DC vaccine could promote an AFP-specific anti-tumor immune response in patients with HCC, and the clinical trial results showed these vaccine-induced CD8+ T-cell responses (25). The gene discussed is CD8A; the disease is neoplasm.